<DOC>
	<DOCNO>NCT00742105</DOCNO>
	<brief_summary>This study confirm safety tolerability determine MTD BGT226 Japanese patient advance solid tumor .</brief_summary>
	<brief_title>Phase I Study Determine Maximum Tolerate Dose ( MTD ) BGT226 Advanced Solid Tumors Japan</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>World Health Organization ( WHO ) Performance Status ≤ 2 Histologicallyconfirmed , advance solid tumor Progressive , recurrent unresectable disease Age ≥ 20 Hematopoietic : No diabetes mellitus history gestational diabetes mellitus No acute chronic renal disease No acute chronic liver disease No acute chronic pancreatitis No impaired cardiac function clinically significant cardiac disease ventricular arrhythmia , congestive heart failure , uncontrolled hypertension No acute myocardial infarction unstable angina pectoris within past 3 month Not pregnant nursing fertile patient must use barrier contraceptive Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>PI3K</keyword>
	<keyword>mTOR</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Adult</keyword>
</DOC>